Generic Gleevec Will Likely Save Millions in Costs
Over 5 years, researchers estimate more than $9 million in insurance savings (Source: WebMD Health)
Source: WebMD Health - March 18, 2016 Category: Consumer Health News Source Type: news
Generic Gleevec Will Likely Cut Millions in Health Costs
Over 5 years, researchers estimate more than $9 million in insurance savings (Source: U.S. News - Health)
Source: U.S. News - Health - March 18, 2016 Category: Consumer Health News Source Type: news
Generic Gleevec Will Likely Cut Millions in Health Costs
FRIDAY, March 18, 2016 -- Using the generic form of the cancer drug Gleevec could save patients and insurers millions of dollars, a new study suggests.
The patent on Gleevec expired in January. The generic version of the drug is called imatinib.
The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 18, 2016 Category: Journals (General) Source Type: news
Generic Gleevec Will Likely Cut Millions in Health Costs
Over 5 years, researchers estimate more than $9 million in insurance savings (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - March 18, 2016 Category: Cancer & Oncology Source Type: news
Generic Gleevec Will Likely Cut Millions in Health Costs
Over 5 years, researchers estimate more than $9 million in insurance savings (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 18, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Oncology, Pharmacy, News, Source Type: news
Generic Gleevec Will Hurt Novartis -- But Save Millions In Health Costs
The pioneering cancer drug Gleevec now faces competition from a cheap generic. A new study says embracing the copycat version could have a huge impact on treatment costs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 16, 2016 Category: Pharmaceuticals Authors: Arlene Weintraub Source Type: news
Using generic cancer drug could save many millions of dollars
With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia (CML) from a death sentence to a treatable illness, insurance companies and patients have the opportunity to realize huge cost savings, new Johns Hopkins Bloomberg School of Public Health research suggests. (Source: World Pharma News)
Source: World Pharma News - March 15, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Using generic cancer drug could save many millions of dollars
(Johns Hopkins University Bloomberg School of Public Health) With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia from a death sentence to a treatable illness, insurance companies and patients have the opportunity to realize huge cost savings, new Johns Hopkins Bloomberg School of Public Health research suggests. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 15, 2016 Category: Cancer & Oncology Source Type: news
Vascular Occlusion Risk Reviewed For CML New-Generation TKIs
A meta-analysis highlights the significantly increased risk of vascular occlusive events in patients with chronic myeloid leukaemia using some new-generation BCR–ABL tyrosine kinase inhibitors compared with use of imatinib. (Source: MedWire News)
Source: MedWire News - February 19, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Sun hopes cut-price generic Gleevec will win third of U.S. market
ZURICH (Reuters) - India's Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by pricing the copycat some 30 percent cheaper, its Sun's North American chief executive said. (Source: Reuters: Health)
Source: Reuters: Health - February 1, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Sun Pharma launches Imatinib Mesylate, incentives to US leukemia patients
Drug maker Sun Pharmaceuticals launched Imatinib Mesylate, the generic copy of anti-cancer drug Gleevec, in the US market enjoying 180 days of exclusivity by USFDA. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 1, 2016 Category: Pharmaceuticals Source Type: news
Novartis taps Hospira-sale engineer exec Ball to revive slumping Alcon
Novartis (NYSE:NVS) is looking to revitalize its slumping Alcon eye care division by picking up medical vet Michael Ball, who recently organized Hospira’s $15 billion sale to Pfizer (NYSE:PFE).
Ball will replace previous Alcon chief Jeff George, the company announced today. Novartis CEO Joe Jimenez is reportedly putting Ball in control of reviving Alcon.
Alcon has been in a rut, with its glaucoma drug Travatan Z patent expiring last month, intraocular lens implant revenue slumping and an underperforming over-the-counter contact lens solution biz.
“If you look at the mistakes that were made that have led to the slow...
Source: Mass Device - January 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Alcon Inc. Hospira Inc. Novartis AG Pfizer Inc. Source Type: news
Summary Information for: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Labeling, Approval Order, and Summary of Safety and Effectiveness for PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) (H140005). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news
Summary Information for: KIT D816V Mutation Detection by PCR for Gleevec Eligibility in Aggressive Systemic Mastocytosis (ASM)
Labeling, Approval Order, and Summary of Safety and Effectiveness for KIT D816V Mutation Detection by PCR for Gleevec Eligibility in Aggressive Systemic Mastocytosis (ASM) (H140006). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news
